Inspira Health Appoints Ankur S. Patel, MD, MBA, FAAFP as President of LIFE Program
VINELAND, N.J.--(BUSINESS WIRE)-- Inspira Health today announced the appointment of Ankur S. Patel, MD, MBA, FAAFP as President of Inspira Living Independently for Elders (LIFE), effective May 5. Dr. Patel brings more than a decade of experience in caring for the elderly in various settings, including acute care, post-acute care, nursing home, and the Program for All-inclusive Care for the Elderly (PACE).
Dr. Patel has developed an expertise in innovative approaches to advancing quality of life while improving overall patient satisfaction and optimizing health care costs and efficiencies. Most recently, Dr. Patel served as Chief Medical Officer at GrayHawk Health, where he drove positive patient health outcomes, and improved overall patient satisfaction and health care costs by ensuring the right care is delivered at the right time in the most effective care settings.
'We are proud to announce Dr. Patel's appointment to Inspira Health,' said April M. Venable, MBA, FACHE, Senior Vice President, Operations Strategy and Transformation at Inspira Health. 'Inspira LIFE's primary mission is to support seniors living independently in their communities, and Dr. Patel will bring tremendous insight and passion to further drive this mission. I am confident that he will make a lasting, invaluable impact on our patients, staff, and community through this critical role.'
As President of LIFE, Dr. Patel will leverage his experience to deliver high-quality, comprehensive health services to LIFE participants by ensuring clinical, operational, and financial excellence. Notably, Dr. Patel previously served as Medical Director for LIFE at Inspira and was instrumental in shaping the LIFE Program in its earlier years.
'I am beyond thrilled to lead Inspira LIFE's mission to deliver integrated, person-centered care that meets the needs of seniors in our community,' said Dr. Patel. 'Throughout my career, I've developed a deep commitment and passion to empower our aging populations to live healthy, independent lives, and I'm looking forward to bringing that to the Inspira community.'
Through his new role, Dr. Patel is positioned to drive innovation, foster employee engagement, and build community and industry partnerships for the program.
Dr. Patel earned his Bachelor of Pharmacy degree from North Gujarat University in India. He holds a medical degree from St. James School of Medicine in Netherlands, Antilles, and an MBA from Isenberg School of Management, University of Massachusetts. Furthermore, he completed his family medicine residency at University of Alabama, Huntsville and geriatric fellowship at Eastern Virginia Medical School in Norfolk, VA. Dr. Patel is the international bestselling author of Age Is Just a Number: A Geriatrician's Secrets to Getting the Most Out of Life.
About Inspira Health
Inspira Health is a charitable nonprofit health care organization committed to providing an exceptional experience for patients and their loved ones. Tracing its roots to 1899, the system comprises four hospitals, two comprehensive cancer centers, nine multi-specialty health centers and locations throughout South Jersey.
Inspira's surgical teams provide a wide array of innovative robotic and minimally invasive surgeries, including nationally accredited bariatric services at Inspira Medical Centers Mullica Hill and Vineland. In partnership with Cooper University Health Care, Inspira provides comprehensive neuroscience and cardiology services throughout the region.
Inspira's extensive ambulatory services include urgent care; ambulatory surgery centers; physical and occupational therapy; comprehensive behavioral health; primary and specialty physician practices; and extensive outpatient imaging in partnership with Atlantic Medical Imaging (AMI). Inspira EMS covers communities throughout South Jersey. Inspira's Population Health and Community Impact Departments address social drivers of health that impact individuals and families in our region.
Inspira's more than 1,400 physicians and advanced practice providers, and 8,000 employees, provide evidence-based care to help each patient achieve the best possible outcome. As a regional leader in physician training, Inspira Health educates and provides extensive clinical opportunities for more than 280 medical residents and fellows in 16 nationally accredited programs.Accredited by DNV Healthcare and committed to the principles of high reliability, Inspira Health is focused on clinical excellence and patient safety. For more information about Inspira Health, visit http://www.InspiraHealthNetwork.org or call 1-800-INSPIRA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 hours ago
- Business Wire
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on ' Beyond Bispecifics and ADCs: Conditionally Active Biologics.' Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs. The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky.
Yahoo
18 hours ago
- Yahoo
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Participants in program for elderly to rally in Lansing against Medicaid cuts
GRAND RAPIDS, Mich. (WOOD) — Potential Medicaid cuts in Congress could impact millions nationwide, including thousands in West Michigan. Advocates: Medicaid 'not a luxury,' lawmakers need plan for fallout At least 200 participants in the Program of All-Inclusive Care for the Elderly, or PACE, are visiting Lansing on Tuesday to urge state lawmakers to protect the program. PACE helps low-income seniors remain in their homes through care funded by Medicaid and Medicare. Sarah Milanowski, enrollment manager at LifeCircles PACE, said the issue affects both state and federal decision-makers. 'Medicaid is a state-administered program that has a portion of its funds from the federal government, and then the state matches funds,' she explained. 'So, as our local lawmakers are planning for their budget into the future, they are trying to hedge their bets about what might or might not be happening in Washington, D.C.' Republicans look for reset on Trump's 'big, beautiful bill' More than 2.6 million Michigan residents rely on Medicaid, according to the Michigan Department of Health and Human Services. That includes the 7,000 who use PACE services for medical care, transportation, prescriptions and more. PACE advocates are scheduled to meet with lawmakers starting at 9:30 a.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
